logo

For the Inventor, By the Inventor

San Carlos, CA, United States of America

Mary B Sliwkowski

This inventor holds 10 USPTO granted patents and 2 EPO patents. Top assignee: Genentech, Inc.. Active years: 1993-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary B Sliwkowski. Retrieved from https://idiyas.com/inventor/mary-b-sliwkowski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 80.0


Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 121(Granted Patents)


Company Filing History:

goldMedal10 out of 3,298 
 
Genentech, Inc.
 patents

Years Active: 1993-2005

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 6932965 - Purified forms of DNase (2005-08-23),
2. 6916916 - Sialidase and recombinant cell lines (2005-07-12),
3. 6562588 - Sialidase and recombinant cell lines (2003-05-13),
4. 6455262 - Receptor polypeptides and their production and uses (2002-09-24),
5. 6440412 - Purified forms of DNase (2002-08-27),
6. 5928915 - CHO cell sialidase by recombinant DNA technology (1999-07-27),
7. 5783433 - Purified forms of DNase (1998-07-21),
8. 5286654 - Detection and purification of activin polypeptide (1994-02-15),
9. 5279823 - Purified forms of DNASE (1994-01-18),
10. 5216126 - Receptor polypeptides and their production and uses (1993-06-01),

Title: Innovator Spotlight: Mary B Sliwkowski

Introduction

Mary B Sliwkowski, a prominent inventor based in San Carlos, California, has made significant contributions to the field of biotechnology through her innovative patents. With a total of 10 patents to her name, Sliwkowski's work focuses on advancements that can improve patient care and therapeutic applications.

Latest Patents

Among her latest patents, one noteworthy invention is the development of purified forms of DNase. This invention details the identification and characterization of two components of a recombinant preparation of DNase, namely the purified deamidated and non-deamidated human DNases. The separation of these components and the application of the non-deamidated species as a pharmaceutical is particularly significant, especially for patients experiencing pulmonary distress.

Another important patent involves the creation of a recombinant cell line with a constitutive sialidase whose functional expression is disrupted. This invention highlights the purification of sialidase from cell culture fluid derived from Chinese hamster ovary cells and describes how nucleic acid encoding sialidase can be obtained using an oligonucleotide probe designed from amino acid sequence data.

Career Highlights

Mary currently works at Genentech, Inc., a leading biotechnology company known for its innovative approaches in drug development. Throughout her career, Sliwkowski has established herself as a key player in the advancement of therapeutic techniques in the biotechnology sector, showcasing her dedication to improving healthcare outcomes.

Collaborations

In her journey, Mary B Sliwkowski has collaborated with esteemed colleagues such as John Frenz and Edward T. Cox. Together, they have engaged in groundbreaking research that has resulted in significant technological advancements in their field.

Conclusion

Mary B Sliwkowski is an exemplary figure in the world of biotechnology and innovation. Her contributions through patent developments reflect her commitment to enhancing patient care and fostering advancements in medical technology. As she continues her work at Genentech, her impact on the industry remains profound.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…